A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
This study will test the safety and efficacy of FOR46 given every 21 days to patients with
metastatic castration-resistant prostate cancer.
The name of the study drug involved in this study is: FOR46 for Injection (FOR46)